Approximately 50–90% of brain metastatic patients who receive radiation therapy (RT) exhibit cognitive decline which may affects the quality of life of cancer survivors. Hence preservation of cognitive functions in brain metastatic patients becomes important. This review aims to evaluates the pathology or mechanism of cognitive function impairment after brain irradiation and strategies available to preserve cognitive function after radiation therapy.
Data Sources
Published articles evaluating the pathology behind radiation induced cognitive impairment and strategies to resolve or preserve cognitive impairment were searched for in scientific databases (eg: PubMed, Scopus, Cochrane database, Google scholar) using keywords including memantine, brain metastases, radiation therapy, pathophysiology, pathogenesis, mechanism and prevention
Data Summary
Several hypotheses have been offered to explain the mechanism of radiation induced cognitive decline. Among them, vascular hypotheses play a significant role. Some pharmacological agents have been also tested in patients receiving radiotherapy, memantine was found beneficial based with the reference to existing data.
Conclusion
Future studies are required to evaluate the impact of memantine in different types of radiation therapy procedures and its effects on quality of life of brain metastatic survivors.
GrausFWalkerRWAllenJC. Brain metastases in children. J Pediatr1983; 103: 558–561.
3.
TabouretEBauchetLCarpentierAF. Brain metastases epidemiology and biology. Bull Cancer2013; 100: 57–62.
4.
TaillibertSLe RhunÉ. Epidemiology of brain metastases. Cancer Radiother2015; 19: 3–9.
5.
SvokosSASalhiaBTomsSA. Molecular biology of brain metastasis. Int J Mol Sci2014; 15: 9519–9530.
6.
WinklerF. The brain metastatic niche. J Mol Med2015; 93: 1213–1220.
7.
LuzziKJMacDonaldICSchmidtEE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micro metastases. Am J Pathol1998; 153: 865–873.
8.
Custodio-SantosTVideiraMBritoMA. Brain metastasization of breast cancer. BiochimBiophys Acta2017; 1868(1): 132–147.
9.
FranchinoFRudaRSoffiettiR. Mechanisms and therapy for cancer metastasis to the BrainFront. Oncol2018; 8: 161.
10.
WartenaRBrandsmaDBelderbosJ. Are memantine, methylphenidate and donepezil effective in sparing cognitive functioning after brain irradiation?J Cancer Metastasis Treat2018; 4: 59.
11.
PatilCGPricolaKSarmientoJM,et al.Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev2017; 9: CD006121. PMID: 28945270; PMCID: PMC6483798.
12.
RooneyJWLaackNN. Pharmacological interventions to treat or prevent neurocognitive decline after brain radiation. CNS Oncol2013; 2, 531–541
13.
MakaleMTMcDonaldCRHattangadi-GluthJA, et al.Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol2017; 13: 52–64. Epub 2016 Dec 16. PMID: 27982041; PMCID: PMC5805381.
14.
JalaliRGuptaTGodaJS, et al. Efficacy of stereotactic conformal radiotherapy vs conventional radiotherapy on benign and Low-grade brain tumors: a randomized clinical trial. JAMA Oncol2017; 3: 1368–1376.
15.
PazzagliaSBrigantiGMancusoM, et al.Neurocognitive decline following radiotherapy: mechanisms and therapeutic implications. Cancers (Basel)2020; 12: 146. PMID: 31936195; PMCID: PMC7017115.
16.
BrownPDPughSLaackNN, et al., Radiation therapy oncology group (RTOG). memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol2013; 15: 1429–1437. Epub 2013 Aug 16. PMID: 23956241; PMCID: PMC3779047.
17.
BelkaCBudachWKortmannRD, et al. Radiation induced CNS toxicity – molecular and cellular mechanisms. Br J Cancer2001; 85: 1233–1239.
18.
ZhouYDanboltNC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna)2014; 121: 799–817. Epub 2014 Mar 1. PMID: 24578174; PMCID: PMC4133642.
19.
BelovKirdajovaDKriskaJTureckovaJ, et al.Ischemia-Triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci2020; 14: 51. PMID: 32265656; PMCID: PMC7098326.
20.
Wong-GoodrichSJPfauMLFloresCT, et al. Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation. Cancer Res 2010; 70: 9329–9338. (2010)
MossASWinteringNRoggenkampH,et al.Effects of an 8-week meditation program on mood and anxiety in patients with memory loss. J Altern Complement Med2012; 18: 48–53. PMID: 22268968.
23.
DinkelKMacPhersonASapolskyRM. Novel glucocorticoid effects on acute inflammation in the CNS. J Neurochem84: 2003; 705–716.
24.
LalithambikaCVArunCSSaraswathyLA, et al.Cognitive impairment and its association with glycemic control in type 2 diabetes Mellitus patients. Indian J Endocrinol Metab2019; 23: 353–356. PMID: 31641638; PMCID: PMC6683683.
25.
YangWCChenYFYangCC, et al., Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial. Neuro Oncol2021; 23: 478–486. Erratum in: Neuro Oncol. 2021; 23(12): 2125. PMID: 32789503; PMCID: PMC7992885.
26.
BrownPDGondiVPughS,et al.for NRG Oncology. Hippocampal avoidance during whole-brain radiotherapy Plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol2020; 38: 1019–1029. Epub 2020 Feb 14. PMID: 32058845; PMCID: PMC7106984.
27.
BrownPDJaeckleKBallmanKV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA.2016; 316: 401–409.
28.
RaberJRolaRLeFevourA, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 2004; 162: 39–47.
29.
ShawEG. Phase II double-blind placebocontrolled study of armodafinil for brain radiation induced fatigue. Presented at: American Society of Clinical Oncology 2013 Annual Meeting. Chicago, IL, USA, 31 May–4 June, 2013(Abstract 9505).
30.
DitzlerK. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo-controlled trial. Arzneimittelforschung1991; 41: 773–780. [PubMed: 178]
31.
KunsBRosaniAVargheseD. Memantine. In: StatPearls Treasure Island (FL): Stat Pearls Publishing. 2021: 1–16.
32.
TampiRRvan DyckCH. Memantine: efficacy and safety in mild-to-severe Alzheimer's Disease. Neuropsychiatr Dis Treat2007; 3: 245–258. PMID: 19300557; PMCID: PMC2654628.
33.
LinXDeAngelisLM. Treatment of brain metastases. J Clin Oncol2015; 33: 3475–3484. Epub 2015 Aug 17. PMID: 26282648; PMCID: PMC5087313.
34.
LambaNMehannaEKearneyRB,et al.Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. J Neurooncol2020;148: 509–517. Epub 2020 May 28. PMID: 32468331.
35.
PooleriGKKleetusJMLaddhaA, et al.Long-term survival in a case of renal cell carcinoma with brain metastases: a case report. Clin Med Insights Case Rep2019; 12: 1179547619854703. PMID: 31258340; PMCID: PMC6587384.
36.
NiuXAnupamaRDelisleM, et al., Brain metastases in women with epithelial ovarian cancer: multimodal treatment including surgery or gamma-knife radiation is associated with prolonged survival. J Obstet Gynaecol Can2013; 35: 816–822.
37.
ZhaoWPayneVTommasiE, et al. Administration of the peroxisomal proliferator-activated receptor g agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Int J Radiat Onco Biol Phys 2004; 67: 6–9.
38.
WatsonGSCholertonBARegerMA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950–958.
39.
LeeTCGreene-SchloesserDPayneV, et al. Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole brain irradiation-induced perirhinal cortex-dependent cognitive impairment. Radiat Res 2012; 178, 46–56.
40.
ConklinHMKhanRBReddickWE, et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, doubleblind, cross-over trial. J Pediatr Psychol32: 2007; 1127–1139.
41.
MeyersCAWeitznerMAValentineAD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16: 2522–2527.
42.
WongPLeppertI. RRobergeD, et al. A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget2016; 7: 50986–50996.
